Improving the detection limit of quantitative diagnosis of anti-S. haematobium antibodies using Falcon Assay Screening Test (FAST) ELISA by developing a new standard curve

Abdelfattah, Mohamed S.; Al-Sherbiny, Maged; Osman, Ahmed; Charmy, Ragia; Tsang, Victor C. W.

doi:10.1007/s00436-010-2198-y

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One practical drawback of ELISA is the time required to perform the test. However, the introduction of the modified Falcon assay screening test (FAST) ELISA, which has a sensitivity and specificity similar to those of conventional ELISA, but with reduced time requirements, has been helpful in large-scale community screening initiatives (137,138). The fraction antigen ELISA (FA-ELISA) is another modified ELISA method, which uses fractionated SEA and provides a high sensitivity and specificity in case detection, as well as providing effective assessment of the efficacy of therapy for S. japonicum infection (139).…”

Section: Antibody Detectionmentioning

confidence: 99%

Advances in the Diagnosis of Human Schistosomiasis

et al. 2015

View full text Add to dashboard Cite

SUMMARY Schistosomiasis is a major neglected tropical disease that afflicts more than 240 million people, including many children and young adults, in the tropics and subtropics. The disease is characterized by chronic infections with significant residual morbidity and is of considerable public health importance, with substantial socioeconomic impacts on impoverished communities. Morbidity reduction and eventual elimination through integrated intervention measures are the focuses of current schistosomiasis control programs. Precise diagnosis of schistosome infections, in both mammalian and snail intermediate hosts, will play a pivotal role in achieving these goals. Nevertheless, despite extensive efforts over several decades, the search for sensitive and specific diagnostics for schistosomiasis is ongoing. Here we review the area, paying attention to earlier approaches but emphasizing recent developments in the search for new diagnostics for schistosomiasis with practical applications in the research laboratory, the clinic, and the field. Careful and rigorous validation of these assays and their cost-effectiveness will be needed, however, prior to their adoption in support of policy decisions for national public health programs aimed at the control and elimination of schistosomiasis.

show abstract

Section: Antibody Detectionmentioning

confidence: 99%

Advances in the Diagnosis of Human Schistosomiasis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Antibody detection assays can be highly specific and sensitive (Abdel-Fattah et al 2011). These tests are promising for the diagnosis of patients living in lowendemicity areas, especially if used concurrently with coproscopy (Gonçalves et al 2006, Igreja et al 2007).…”

mentioning

confidence: 99%

Schistosoma mansoni in a low-prevalence area in Brazil: the importance of additional methods for the diagnosis of hard-to-detect individual carriers by low-cost immunological assays

Grenfell¹,

Martins²,

Enk³

et al. 2013

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…mansoni and S . haematobium [32, 33]. SEA ELISAs and species-specific immunoblots were performed by the Parasitic Diseases Branch of the CDC and CAA testing was performed at Leiden University Medical Center.…”

Section: Methodsmentioning

confidence: 99%

Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies

et al. 2019

View full text Add to dashboard Cite

BackgroundMany regions of sub-Saharan Africa experience a high prevalence of both schistosomiasis and HIV-1, leading to frequent coinfection. Higher plasma HIV-1 viral loads are associated with faster disease progression and genital HIV-1 loads are a primary determinant of HIV-1 transmission risk. We hypothesized that schistosome infection would be associated with higher HIV-1 viral loads in plasma and genital samples.Methods/Principal findingsWe utilized data from individuals who HIV-1 seroconverted while enrolled in one of four prospective cohort studies. Plasma and genital viral loads collected 4–24 months after the estimated date of HIV-1 acquisition, but prior to antiretroviral therapy initiation, were included. Detection of circulating anodic antigen in archived blood samples, collected prior to HIV-1 seroconversion, identified participants with active schistosomiasis; immunoblots determined the schistosome species causing infection. Our analysis included 370 HIV-1 seroconverters with plasma viral load results, of whom 82 (22%) had schistosomiasis. We did not find a statistically significant association between schistosomiasis and higher HIV-1 set point plasma viral loads (-0.17 log10 copies/ml, 95% CI -0.38 to 0.03); S. mansoni infection was associated with a lower set point (-0.34 log10 copies/ml, 95% CI -0.58 to -0.09). We found no association between schistosomiasis and cervical (+0.07 log10 copies/swab, 95% CI -0.20 to 0.34) or vaginal (+0.11 log10 copies/swab, 95% CI -0.17 to 0.39) set point viral loads; S. haematobium infection was associated with lower cervical viral loads (-0.59 log10 copies/swab, 95% CI -1.11 to -0.06).Conclusions/SignificanceThese results do not support the hypotheses that schistosome coinfection increases plasma or genital HIV-1 viral loads.

show abstract

Improving the detection limit of quantitative diagnosis of anti-S. haematobium antibodies using Falcon Assay Screening Test (FAST) ELISA by developing a new standard curve

Cited by 12 publications

References 17 publications

Advances in the Diagnosis of Human Schistosomiasis

Advances in the Diagnosis of Human Schistosomiasis

Schistosoma mansoni in a low-prevalence area in Brazil: the importance of additional methods for the diagnosis of hard-to-detect individual carriers by low-cost immunological assays

Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies

Contact Info

Product

Resources

About